Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy

被引:21
作者
Ayas, M
Al-Jefri, A
Al-Mahr, M
Rifai, S
Al-Seraihi, A
Tbakhi, A
Mustafa, M
Khairy, A
Moussa, E
Iqbal, A
Shalaby, L
El-Solh, H
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Riyadh 11211, Saudi Arabia
[3] King Hussein Canc Ctr, Dept Pediat, Amman, Jordan
关键词
Fanconi anemia; cyclophosphamide; antithymocyte globulins; stem cell transplantation;
D O I
10.1038/sj.bmt.1704787
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
In all, 22 patients with confirmed Fanconi anemia ( FA) underwent stem cell transplantation ( SCT) from HLA-matched, related donors at KFSHRC. Median age at SCT was 7.6 years ( range, 2.5 - 14.6 years). Conditioning regimen consisted of cyclophosphamide ( CY) 15 mg/ kg/ day intravenously ( i. v.) for 4 consecutive days, in addition to equine antithymocyte globulins ( ATG) given i. v. at 40 mg/ kg/ day for four doses pre- SCT. No radiation therapy was given. For graft- versus- host disease prophylaxis, we used cyclosporin at the standard doses; ATG was added at 20 mg/ kg/ dose i. v. on days 2, 4, 6, 8, 10, and 12 post- SCT ( total of six doses). All patients engrafted and are alive and transfusion independent with a median follow- up time of 20.2 months ( range, 3.3 - 59 months). One patient however developed a decrease in her WBC and platelet count. Her work- up revealed slightly hypocellular bone marrow, and a series of chimerism studies over 1 year confirmed that she has stable mixed chimerism; she remains transfusion independent. We conclude that low- dose CY without radiation therapy can be used satisfactorily in the conditioning of patients with FA undergoing related SCT.
引用
收藏
页码:463 / 466
页数:4
相关论文
共 26 条
  • [1] Cancer in Fanconi anemia
    Alter, BP
    Greene, MH
    Velazquez, I
    Rosenberg, PS
    [J]. BLOOD, 2003, 101 (05) : 2072 - 2073
  • [2] FANCONI-ANEMIA AND ITS VARIABILITY
    ALTER, BP
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1993, 85 (01) : 9 - 14
  • [3] ALTER BP, 1992, AM J PEDIAT HEMATOL, V14, P170
  • [4] ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P259
  • [5] LEUKEMIA AND PRELEUKEMIA IN FANCONI ANEMIA PATIENTS - A REVIEW OF THE LITERATURE AND REPORT OF THE INTERNATIONAL FANCONI ANEMIA REGISTRY
    AUERBACH, AD
    ALLEN, RG
    [J]. CANCER GENETICS AND CYTOGENETICS, 1991, 51 (01) : 1 - 12
  • [6] Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation
    Ayas, M
    Al-Jefri, A
    Al-Mahr, M
    Rifai, S
    Moussa, E
    Karaoui, M
    Roberts, G
    El-Solh, H
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 (01) : 15 - 17
  • [7] Does adding ATG to the GVHD prophylaxis regimen help reduce its incidence?
    Ayas, M
    Al-Mahr, M
    Al-Jefri, A
    Rifai, S
    Solh, H
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 (04) : 311 - 311
  • [8] Bone marrow transplantation from matched siblings in patients with Fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin
    Ayas, M
    Solh, H
    Mustafa, MM
    Al-Mahr, M
    Al-Fawaz, I
    Al-Jefri, A
    Shalaby, L
    Al-Nasser, A
    Al-Sedairy, R
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 (02) : 139 - 143
  • [9] Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG)
    Bacigalupo, A
    Oneto, R
    Lamparelli, T
    Gualandi, F
    Bregante, S
    Raiola, AM
    Di Grazia, C
    Dominietto, A
    Romagnani, C
    Bruno, B
    Van Lint, MT
    Frassoni, F
    [J]. BONE MARROW TRANSPLANTATION, 2001, 28 (12) : 1093 - 1096
  • [10] Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors
    de la Fuente, J
    Reiss, S
    McCloy, M
    Vulliamy, T
    Roberts, IAG
    Rahemtulla, A
    Dokal, I
    [J]. BONE MARROW TRANSPLANTATION, 2003, 32 (07) : 653 - 656